A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
Astellas Pharma Inc
AbbVie
Travera Inc
Eli Lilly and Company
OncoC4, Inc.
Jazz Pharmaceuticals
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Alliance for Clinical Trials in Oncology
Pfizer
Amgen
Arcus Biosciences, Inc.
AstraZeneca
Eli Lilly and Company
UMC Utrecht
Neonc Technologies, Inc.
ViroMissile, Inc.
UNC Lineberger Comprehensive Cancer Center
Duke University
Washington University School of Medicine
University of California, San Diego
Baylor College of Medicine
SystImmune Inc.
xCures
Daiichi Sankyo
University of Nebraska
Takeda
Adela, Inc
Perspective Therapeutics
Second Life Therapeutics
M.D. Anderson Cancer Center
Novartis
Var2 Pharmaceuticals
VM Oncology, LLC
University Hospital, Lille
Tanabe Pharma America, Inc.
Mayo Clinic
NeoTX Therapeutics Ltd.
University of Connecticut
Tempus AI
Massive Bio, Inc.
Incyte Corporation
Immunitas Therapeutics
Actym Therapeutics, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
University of Colorado, Denver